{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-004178","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2026-08-18T12:00:59+00:00","discovered_at":"2026-08-18T12:05:00.796972+00:00","generated_at":"2026-08-18T12:05:11.007316+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Entera Bio appoints Riccardo Paolo Camisasca as CMO ahead of EB613 Phase 3","bullets":["Dr. Riccardo Paolo Camisasca appointed Chief Medical Officer effective Aug 18, 2026.","He brings 30+ years experience; most recently Global Head of R&D at Sumitomo Pharma Switzerland.","Appointment strengthens clinical team ahead of planned EB613 Phase 3 initiation for osteoporosis.","Previously led R&D integration across Urovant, Enzyvant, Altavant, and Myovant at Sumitomo.","CEO Miranda Toledano cites his rare combination of developing drugs across global R&D organizations."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-004178","json":"https://secwatch.observer/filing/0001178913-26-004178.json","markdown":"https://secwatch.observer/filing/0001178913-26-004178.md","text":"https://secwatch.observer/filing/0001178913-26-004178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326004178/0001178913-26-004178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326004178/zk2635983.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-18T12:05:11.007316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}